Cilnidipine acts on the L-type calcium channels of blood vessels by blocking the incoming calcium and suppressing the contraction of blood vessels, thereby reducing blood pressure. Cilnidipine also works on the N-type calcium channel located at the end of the sympathetic nerve, inhibiting the emission of norepinephrine and suppressing the increase in stress blood pressure.
Clinlpin 5 Tablet: Each film-coated tablet contains Cilnidipine INN 5 mg.
Cilnipin 10 Tablet: Each film-coated tablet contains Cilnidipine INN 10 mg.
The recommended adult oral dosage of Cilnipin is 5-10 mg once daily, after breakfast. The dosage can be increased up to 20 mg daily, if needed or as decided by the physician.
Cilnidipine is contraindicated in hypersensitivity to Cilnidipine or to any of the excipients of Cilnidipine. It is also contraindicated in cardiogenic shock, recent Ml or acute unstable angina, severe aortic stenosis.
Dizziness, flushing, headache, hypotension, peripheral edema, tachycardia, palpitations, GI disturbances, increased micturition frequency, lethargy, eye pain, depression, ischemic chest pain, cerebral or myocardial ischemia, transient blindness, rashes, fever, abnormal liver function, gingival hyperplasia, myalgia, tremor, impotence.
Other antihypertensives, aldesleukin, antipsychotics that cause hypotension, may modify insulin and glucose responses, quinidine, carbamazepine, phenytoin, rifampicin, cimetidine, erythromycin.
Hypotension, poor cardiac reserve, heart failure, sudden withdrawal may exacerbate angina. Discontinue in patients who experience ischemic pain following administration. Pregnancy, lactation.
USE IN SPECIFIC POPULATION Use in pregnancy: Cilnidipine should not be administered to pregnant women or women having possibilities of being pregnant. Use in lactation: It is advisable to avoid the administration of Cilnidipine to nursing mothers. However, if the administration is indispensable, the patient should be instructed to discontinue lactation. Use in children: The safety of Cilnidipine in pediatric patients has not been established (no clinical experience). Use in the elderly: Cilnidipine should be administered carefully under close observation of the patient's condition, taking such measures as starting with a lower dose (e.g, 5 mg). It is generally acknowledged that the excessive hypotensive action should be avoided in the elderly. Use in renal and hepatic impaired patients: The pharmacokinetics of Cilnidipine have been evaluated in patients with impaired renal function (serum creatinine: 1.5 3.1 mg/dl) following a single oral dose of 10 mg and repeated dose of 10 mg once a day for 7 days in the hypertensive patients and no significant differences were found in the pharmacokinetic profile of Cilnidipine compared with that in patients with normal renal function. No data is available for hepatic impaired patients.
Cilnipin 5 Tablet: Each box contains 30 tablets in alu-alu blister pack. Clinlpin 10 Tablet: Each box contains 30 tablets in alu-alu blister pack
FR
DE